Medtronic teams up with ARCA for a-fib trial

ARCA Biopharma ($ABIO) is planning a Phase IIb/III trial of Gencaro, an investigational atrial fibrillation drug, and Medtronic ($MDT) has signed on to outfit each patient with an implanted CRT-D, measuring the therapy's effect. ARCA is starting with 200 patients in Phase IIb before, depending on results, rolling the study into a 420-patient Phase III trial. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.